Monopar Therapeutics Inc.

Contributing Author

Recent Articles by Monopar Therapeutics Inc.

Oct-15	Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting 2025 MNPR GlobeNewswire
Sep-23	Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants MNPR GlobeNewswire
Sep-23	Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients MNPR GlobeNewswire
Sep-14	Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting MNPR GlobeNewswire
Sep-03	Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting MNPR GlobeNewswire
Aug-12	Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments MNPR GlobeNewswire
Jun-11	Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers MNPR GlobeNewswire
Jun-03	Monopar Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes MNPR GlobeNewswire
May-13	Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments MNPR GlobeNewswire
May-07	Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 MNPR GlobeNewswire